Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mercy Bioanalytics Inc. has 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 7 distinct examiners and 5 distinct art units. This indicates that every pending application is being reviewed by a different person, and the work is spread across several technical groups. CHAN, KO HUNG is the busiest examiner for the company, currently managing 1 busiest examiner pending action.
The presence of 5 distinct art units suggests a diverse range of biotechnological research being patented. With 7 distinct examiners involved, the company must navigate various examination styles. CHAN, KO HUNG is responsible for 1 of the 7 total pending office actions, which is the same amount as the other examiners. The 5 distinct art units suggest that the 7 pending office actions cover a variety of specialized topics within Biotechnology & Pharmaceuticals. This decentralized prosecution environment requires managing 7 distinct examiners across 5 different art units, ensuring that the company's diverse research portfolio is effectively represented across multiple specialized divisions at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (67%) |
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HANEY, AMANDA MARIE | 1 | 36.5% | +45.0% |
| DAUNER, JOSEPH G | 1 | 57.0% | +35.3% |
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.3% |
| KIM, YOUNG J | 1 | 64.8% | +18.2% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| RAMADAN, OMAR | 1 | 25.4% | +56.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580422 | COMPOSITIONS AND METHODS FOR DETECTION OF LIVER CANCER | KIM, YOUNG J | 33d |
| 18580444 | COMPOSITIONS AND METHODS FOR DETECTION OF COLORECTAL CANCER | HANEY, AMANDA MARIE | — |
| 18580412 | COMPOSITIONS AND METHODS FOR DETECTION OF PANCREATIC CANCER | DAUNER, JOSEPH G | — |
| 18580427 | COMPOSITIONS AND METHODS FOR DETECTION OF BREAST CANCER | CASH, KAILEY ELIZABETH | — |
| 17435697 | SYSTEMS, COMPOSITIONS, AND METHODS FOR TARGET ENTITY DETECTION | RAMADAN, OMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580422 | COMPOSITIONS AND METHODS FOR DETECTION OF LIVER CANCER | KIM, YOUNG J | 33d |
| 18580444 | COMPOSITIONS AND METHODS FOR DETECTION OF COLORECTAL CANCER | HANEY, AMANDA MARIE | — |
| 18580412 | COMPOSITIONS AND METHODS FOR DETECTION OF PANCREATIC CANCER | DAUNER, JOSEPH G | — |
| 18580440 | COMPOSITIONS AND METHODS FOR DETECTION OF ESOPHAGEAL CANCER | WOOLWINE, SAMUEL C | — |
| 18580427 | COMPOSITIONS AND METHODS FOR DETECTION OF BREAST CANCER | CASH, KAILEY ELIZABETH | — |
| 17435697 | SYSTEMS, COMPOSITIONS, AND METHODS FOR TARGET ENTITY DETECTION | RAMADAN, OMAR | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1681 | 2 |
| 1683 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580444 | COMPOSITIONS AND METHODS FOR DETECTION OF COLORECTAL CANCER | HANEY, AMANDA MARIE | 1682 | §101§102§103§112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18580412 | COMPOSITIONS AND METHODS FOR DETECTION OF PANCREATIC CANCER | DAUNER, JOSEPH G | 1682 | §101§103§112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18580440 | COMPOSITIONS AND METHODS FOR DETECTION OF ESOPHAGEAL CANCER | WOOLWINE, SAMUEL C | 1681 | §112 | Final Rejection | — | Pending | Jan 18, 2024 |
| 18580422 | COMPOSITIONS AND METHODS FOR DETECTION OF LIVER CANCER | KIM, YOUNG J | 1681 | §101§112 | Final Rejection | 33d | Pending | Jan 18, 2024 |
| 18580427 | COMPOSITIONS AND METHODS FOR DETECTION OF BREAST CANCER | CASH, KAILEY ELIZABETH | 1683 | §101§103§112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 17435697 | SYSTEMS, COMPOSITIONS, AND METHODS FOR TARGET ENTITY DETECTION | RAMADAN, OMAR | 1678 | §103Other | Non-Final OA | — | Pending | Sep 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMercy Bioanalytics Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Amanda Marie Haney has the most, with 1 of Mercy Bioanalytics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
